NorthStar Medical Radioisotopes, LLC, a global company in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Convergent Therapeutics, Inc., a clinical stage radiopharmaceutical company, recently announced the signing of a long-term supply agreement for the therapeutic medical radioisotope, actinium-225 (Ac-225). Under the terms of the agreement, NorthStar will provide Convergent with its environmentally preferred, high purity non-carrier-added (n.c.a) Ac-225. Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody, currently being investigated as a potentially ground-breaking treatment for prostate cancer.
Clinical
research and commercial use of Ac-225 are severely constrained by chronic short
supply issues due to the limitations of the current production technology.
NorthStar is well-positioned to be the first commercial-scale producer of
Ac-225 for advancing clinical research and commercial radiopharmaceutical
products. The Company will use its
electron accelerator technology to produce n.c.a. Ac-225.
To
read more please visit:
Source:
NorthStar